3,344.00
+1.10%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ajanta Pharma
Its shares trade on NSE under the ticker AJANTPHARM.NS. It has been listed since 5 June 2000. In the fiscal year to 31 March 2026, it reported revenue of ₹54.53bn and net income of ₹10.56bn. At that date it held total assets of ₹61.55bn and shareholders' equity of ₹45.27bn.
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2000-06-05. The Company’s marketing network operates in domestic and international markets. The firm produces a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market it is present in. The branded generics business is spread in India and approximately 30 emerging countries across Africa, South-East Asia, West Asia, and The Commonwealth of Independent States (CIS). The company has product portfolio includes complex technology products. The firm has also made substantial investments in its research and development (R&D) facilities.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Jun 2000
- Employees
- 7,234
- Website
- ajantapharma.com ↗
Leadership
Pay as last reported
- Mr. Mannalal AgrawalNon-Executive Chairman of the Board₹753,000
- Mr. Madhusudan AgrawalExecutive Vice Chairman of the Board, since 1979₹48.4m
- Mr. Arvind AgrawalChief Financial Officer₹18.4m
- Mr. Gaurang ShahVice President - Legal, Company Secretary₹9.7m
- Mr. Rajesh AgrawalJoint Managing Director, Executive Director, since 2013₹246.4m
- Mr. Yogesh AgrawalManaging Director, Executive Director, since 2000₹246.4m
- Mr. Rajesh DalalAdditional Non-Executive Independent Director₹895,000
- Mrs. Medha JoshiAdditional Non-Executive Independent Director₹795,000
- Ms. Simi Lal ThaparAdditional Non-Executive Independent Director₹795,000
- Mr. David RasquinhaAdditional Non-Executive Independent Director₹995,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 99
- Social
- 96
- Governance
- 22
- Direct emissions (scope 1)
- 6,390.22 t
- Energy emissions (scope 2)
- 40,007.74 t
- Women in the workforce
- 8.72043%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ajanta Pharma Ltd has a strong market presence in the pharmaceutical industry with a wide range of products.
- The company has a well-established distribution network, ensuring efficient supply chain management.
- Ajanta Pharma Ltd has a strong research and development team focused on innovation and product development.
Weaknesses
- The company has a significant dependence on a few key drugs, which exposes it to potential market fluctuations.
- Ajanta Pharma Ltd faces challenges in penetrating certain international markets due to regulatory requirements and competition.
- The company has limited presence in the generic drug segment, which may impact its competitive advantage.
Opportunities
- The growing demand for pharmaceutical products, particularly in emerging markets, provides a significant opportunity for Ajanta Pharma Ltd to expand its customer base.
- Ajanta Pharma Ltd can leverage advancements in technology and invest in research to develop new and more effective drugs.
- Expansion into untapped markets and strategic alliances with other companies can help Ajanta Pharma Ltd increase its global footprint.
Threats
- Intense competition from both domestic and international pharmaceutical companies poses a threat to Ajanta Pharma Ltd's market share.
- Changes in government regulations and pricing policies can significantly impact the profitability of Ajanta Pharma Ltd.
- The risk of patent expiration and the resulting entry of generic competitors can affect the sales of Ajanta Pharma Ltd's branded drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.